Agilent Resolution ctDx FIRST gets FDA approval as NSCLC test

Agilent Technologies "announced that the FDA has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced non-small cell lung cancer, NSCLC, patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM, or adagrasib. This is the first liquid biopsy NGS assay approved by the FDA as a CDx for the newly approved KRAZATI in advanced NSCLC and was developed in collaboration with Mirati Therapeutics. ctDx FIRST has also been approved by the FDA for tumor profiling of the epidermal growth factor receptor gene for use by qualified health care professionals in accordance with professional guidelines in oncology patients with NSCLC."